Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised, double-blind, placebo-controlled trial

Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised, double-blind, placebo-controlled trial Article

authors

publication date

2018

webpage

Web of Science

published in

LANCET INFECTIOUS DISEASES Journal

start page

1241

end page

1250

volume

18

issue

11